NCT043642306MHPhigh-risk melanomaCDX-1140melanomamBRAFpoly-ICLC
…reatment were enrolled to this nonrandomized phase I/II trial ( NCT04364230) designed to assess safety and immunogenicity. Participants rec…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04364230 ×
NCT04364230
This institution is selected. Its supporting articles are shown below.